RxDoctor Payments Data

Jessy Young, NP

Primary Care · Corte Madera, CANPI 1194501908

Payments from drug & device makers

$1,928in general payments, 2019–2025

Across 67 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$515
  • AbbVie$474
  • Madrigal Pharmaceuticals$193
  • Gilead$129
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$110
  • Takeda Pharmaceuticals U.S.A., Inc.$99
  • plus $408 from 11 others

What the payments were for

  • Food & beverage$1,82995%
  • Education$995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,928 in reported general payments places this provider in the 85th percentile of 706 primary care providers in California.

See all primary care providers in California

Medicare billing

Part B allowed, 2024
$98,149
Medicare patients
545
Services billed
649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClenpiqSod Picosulf/Mag Ox/Citric Ac150$25,820
CreonLipase/Protease/Amylase13$25,296
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates303$19,655
LinzessLinaclotide15$12,831
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,640
Omeprazole146$1,797
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg67$1,458
Pantoprazole Sodium57$1,381
Famotidine46$581
Ondansetron OdtOndansetron17$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$474$38,12728 claims
Braintree Laboratories, Inc.Sutab$25$2,64016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 706 primary care providers in California.

Other primary care in Corte Madera

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →